Name: SALBUTAMOL (VentolinR)
Classification: beta2 agonist, bronchodilator
Dose:
  • Inhalation:
    • 0.25 to 0.5 mg (up to 1 mg) q 4 - 6 h 
  • IV bolus: 
    • 250 mcg (~ 4 mcg/kg) over 2-5 mins
  • Infusion:
    • 5 mcg/min, increase by 5 mcg/min to a maximum of 20 mcg/min 
Administration: IV Infusion:
5 mg/500 mL D5W, NS
  • dextrose containing solutions may be inappropriate for patients with diabetes because of salbutamol induced exaggerated hyperglycemia
Adverse Effects: more common with parenteral therapy than inhalational therapy
  • with inhalation:
    • headache
    • nervousness, tremor
    • tachycardias
  • with intravenous therapy:
    • hypertension or hypotension
    • hyperglycemia
    • hypokalemia
    • palpitations
    • arrhythmias
Caution:
  • in patients with cardiovascular disorders, hyperthyroidism and diabetes
Drug Interactions:
  • salbutamol + sympathomimetics = exacerbation of cardiovascular effects
  • salbutamol + beta blockers = mutual antagonism of therapeutic effect 
  • salbutamol + general anaesthetics = decreased BP, increased HR
Monitoring Therapy:
  • Efficacy:
    • breath sounds
    • respiratory rate
    • ventilatory pressures
    • blood gases
  • Adverse effects:
    • heart rate, ECG
    • BP 
    • serum glucose 
    • serum potassium
CCTC Protocol:
  • May be administered by IV infusion by an RN.
  • Continuous infusion must be administered via an infusion pump.
  • With IV use, patient requires placement of an arterial line .
  • With IV use, patient must have continuous ECG monitoring.
  • The physician must be present at the initiation of intravenous therapy; subsequent monitoring may be done by an RN.


Lynne Kelly, Pharmacist, CCTC
Brenda Morgan, Clinical Nurse Specialist, CCTC
Last Update: August 7, 2006

LHSCHealth Professionals

Last Updated March 24, 2009 | © 2007, LHSC, London Ontario Canada